H uman soft tissue defects exact a tremendous medical and emotional burden on patients. 1 Their etiologic footprint is expansive, spanning rare congenital soft tissue syndromes to defects acquired secondary to trauma, oncologic resection, or to diseases. 2 Disordered soft tissue development manifests in several rare but debilitating congenital syndromes, including craniofacial microsomia and Treacher Collins syndrome. 3 Beyond congenital etiologies, soft tissue deficits are acquired either with degenerative conditions such as Parry-Romberg syndrome, or operatively, such as those resulting from oncologic resections of head and neck malignancies. Finally, disease processes can lead to soft tissue loss, as seen with HIV lipodystrophy, a condition affecting 40% to 50% of HIV patients undergoing highly active antiretroviral therapy with first-generation thymidine nucleoside analog reversetranscriptase inhibitors. 4 The disease manifests with atrophy of malar and temporal soft tissue, as well as with peripheral fat wasting in the limbs and buttocks. 4 A multitude of strategies have been advanced to address soft tissue reconstruction, and they center on the broader themes of de novo adipose tissue formation, autologous fat transfer, cell-based therapy, and nonbiologic injectable fillers. De novo tissue formation refers to the guided differentiation of cells towards an adipogenic lineage. Several commercially available cell lines have demonstrated the ability to differentiate into fat cells, in vitro and in vivo, with and without exogenous inductive signaling from adipogenic growth factors. [5] [6] [7] [8] Perhaps more relevant to the in vivo biology of adipogenesis, primary cells also have been successfully induced to fat differentiation, the most studied of which being human mesenchymal stem cells, 9, 10 including bone marrow stem cells 11 and adipose-derived stromal cells. 12 As previously alluded to, some of this differentiation toward the adipogenic fate is attributable to the inclusion of growth factors well known to potentiate adipogenic differentiation-fibroblast growth factor-2, 13 insulin-like growth factor-1, 14 matrix metalloproteinases, 15 and platelet-derived growth factor. 16 In contrast to the nascent promise of de novo adipogenesis, autologous fat grafting has emerged over the past 2 decades as the preeminent technique for managing soft tissue defects. However, despite its ubiquity, the use of fat grafting has been plagued by highly variable clinical results, with some studies reporting retention rates ranging from 10% to 80%. 17, 18 Given the complications and unpredictability of adipose tissue grafting, alternative synthetic fillers -most notably hyaluronic acid-based dermal fillers -have been popularly used in soft tissue reconstruction. Hyaluronic acid-based injectable fillers largely avoid the variability of adipose tissue quality while also minimizing donor site morbidity. 19 In general, patients report satisfaction with the cosmetic results of HA dermal fillers and endorse an increase in quality of life secondary to the therapy. 20 However, the rapidly absorbent nature of the hyaluronic acid-based injectable fillers greatly concede the durability of their desirable effects. Thus, the challenge remains to develop a synthetic vehicle for a cell-based approach capable of replacing human adipose tissue.
Renevia (BioTime, Inc; Alameda, CA) is a hyaluronin-gelatin crosslinked matrix scaffold that is marketed as an alternative to adipose transfer in soft tissue reconstruction. It is designed to emulate the native extracellular matrix (ECM) environment, and by doing so, supports stromal vascular fraction (SVF) cell attachment, survival, and proliferation, thus promoting durable cell-based volume restoration. Currently, the Renevia scaffold is undergoing a Phase III pivotal clinical trial in Europe, in which its use in correcting subcutaneous facial lipoatrophy attributable to HIV is being evaluated. In that trial, the Renevia scaffold is supplemented with SVF cells at concentrations ranging from 3 to 8 million cells per microliter of scaffold. However, the threshold concentration for a clinically relevant result with cell-based therapy has yet to be determined. This present study uses a titration experiment to evaluate multiple concentrations of SVF cells, the results of which enhance our understanding of Renevia cell-based therapy for soft tissue reconstruction.
METHODS

Fat Harvesting/SVF Cell Isolation
In accordance with the Stanford University Institutional Review Board Guidelines, human lipoaspirate was obtained from a single female donor (age, 47 years; body mass index, 26) with no significant medical comorbidities undergoing suction assisted liposuction. Immediately upon receipt from the operating room, the lipoaspirate was twice washed with phosphate-buffered saline (Thermo Fisher Scientific, Waltham, MA) and centrifuged at 350g for 5 minutes, thus permitting separation and removal of excess blood and oil. A fraction of the lipoaspirate designated for grafting was set aside and refrigerated at 4°C. The remainder of the lipoaspirate was digested with collagenase (Sigma-Aldrich, St. Louis, MO) at 37°C for 30 minutes under moderate agitation on an orbital shaker. The digested product was then centrifuged at 350g for 10 minutes at 4°C. The resultant pellet, containing the SVF cells, was suspended in conventional Dulbecco's Modified Eagle Medium (Thermo Fisher Scientific) cell culture media, processed through a 100-micron filter (BD Falcon, Franklin Lakes, NJ), and resuspended in Red Blood Cell Lysis Buffer (Sigma-Aldrich). Upon removal of the red blood cells, the product was gently pipetted atop Histopaque 1077 (Sigma-Aldrich) and centrifuged at 400g for 30 minutes at room temperature. This stratified the heterogeneous mixture into distinct layers, thus enabling precise isolation and removal of the SVF cell layer. The total SVF cell yield was calculated via hemocytometer.
Scaffold Reconstitution and Supplementation
The Renevia scaffold was prepared in accordance with the manufacturer's protocol. Briefly, the individual vials of Glycosil, Gelin, and Extralink lyophilized solids were separately reconstituted with sterile water. The Glycosil and Gelin solutions were combined, and this mix was added to the Extralink vial. After 15 minutes at room temperature, the combined solution attained sufficient viscosity to enable grafting into the unsupplemented scaffold mouse group. The SVF cell-supplemented grafts were prepared by incorporating the appropriate quantity of SVF cells into the Glycosil/Gelin solution, before delivery into the Extralink. Three concentrations of cell-supplemented scaffold were created: 1 million human SVF cells per mL of Renevia scaffold, 6 million human SVF cells per mL scaffold and 12 million human SVF cells per mL scaffold. Separate 1 mL syringes were prepared for the 3 SVF concentrations and for scaffold only. A fifth syringe was prepared containing adipose tissue, only.
Grafting
Thirty-five immunodeficient Crl:CD1-Foxn1 nu CD-1 Nude mice (Charles River Laboratories, Inc, Wilmington, MA) were segregated into 5 experimental groups: 1 million SVF cells per mL Renevia scaffold, 6 million SVF cells per mL scaffold, 12 million SVF cells per mL scaffold, Renevia scaffold-alone, and adipose tissue-alone (N = 7 animals per group). The mice were anesthetized with 2.5% isoflurane gas delivered through a mask. Two hundred fifty microliter Renevia grafts both with and without SVF cells were placed subcutaneously into the scalps of the CD-1 mice. Two hundred fifty microliter fat-alone grafts also were placed, as a control. All injections were performed using a 20-gauge needle, and delivered in retrograde fashion as previously described by Chung et al. 17 
Volumetric Assessment
Volumetric analysis was conducted at discrete time points (day 0, 1, 3; week 1, 2, 4, 6, 8, 10, 13, and 16) using 3-dimensional ultrasound. Images were captured with the FujiFilm VisualSonics Vevo 2100 highfrequency digital imaging platform (FujiFilm VisualSonics Inc.; Toronto, Ontario, Canada) using a 40-MHz ultrasound transducer. The mice were anesthetized with 2.5% isoflurane gas delivered through a mask. Cardiac status was monitored via stage-integrated electrocardiogram pads. Image capture was gated to respiratory cycle to minimize motion artifact. Volume reconstruction and quantification was accomplished on the Vevo LAB software suite (Fig. 1) .
Histology
Mice were sacrificed at week sixteen for histologic analysis. Grafts were explanted in their entirety through a dorsal incision made into the 
Statistics
Statistical analysis was performed on Prism (GraphPad Software, Inc., La Jolla, CA). Intergroup variance was evaluated using 1-way analysis of variance. A P value less than 0.05 was considered statistically significant.
RESULTS
All grafts were placed successfully into the experimental animals, with no evidence of acute infection or rejection. The surgeries were well tolerated by the mice. At the conclusion of the study, the Renevia scaffold group supplemented with the highest concentration of human SVF cells (12 million cells per mL scaffold) had significantly greater percentage volume retention (34.97%; SD, 5.55) when compared with the adipose-alone group (24.63%; SD, 2.85), the one million cells per mL scaffold group (10.31%; SD, 5.70), the six million cells per mL scaffold group (9.80%; SD, 1.30), and the scaffold-alone group (16.76%, SD 0.41) at week 16 (analysis of variance, *P < 0.05) (Fig. 2) . After injection, the adipose-alone group had significantly greater mean volume retention compared with all other groups beginning at day 3 and continuing through week 4 measurements (*P < 0.05). This trend continued up to week 10, at which point an average of 44.58% was noted (SD, 18.43); however, this value was not statistically significant compared with the average of the next closest group, the 12 million scaffold group (34.85%; SD, 7.65; P = 0.722). After week 14, the 12 million group surpassed the adipose-alone group and thereafter became the highest percentage retention group for the remainder of the study. The one million and six million SVF cells per mL scaffold groups performed similarly to the scaffold-alone group throughout the experiment. Taken together, the 4 cohorts using the Renevia scaffold all experienced a precipitous drop in volume in the initial segment of the experiment, losing approximately half their volume in the first week after surgery.
Histology specimens procured at week 16 grossly demonstrated elements of fibrous connective tissue bridging, neovascularization, and adipocyte formation that were variable in distribution and magnitude across all samples.
Hematoxylin and eosin histology of the 12 million scaffold group revealed abundant adipocyte formation within the scaffold, itself (Fig. 3A) . The degree of adipocyte formation in the 12 million group grossly exceeded that of the 6 million (Fig. 3B), 1 million (Fig. 3C) , and scaffold-alone (Fig. 3D) groups.
As anticipated, the greatest number of adipocytes was observed in the H&E preparations of the adipose tissue-alone group (Fig. 3E) . Among the Renevia experimental groups, the 12 million cohort also demonstrated increased formation of fibrous connective tissue integrated throughout the scaffold (Fig. 3F) as compared with the scaffold-only group.
The presence of vascularity was determined by CD31 positive staining, as quantified by ImageJ software. The pattern of staining was largely peripheral to the mature adipocytes; however, the presence of endothelial cells was observed to a limited extent in close proximity to the adipocytes of the scaffold in the 12 million group (Fig. 4A) . The 6 million (Fig. 4B), 1 million (Fig. 4C) , and scaffold-alone (Fig. 4D) groups together demonstrate the least CD31 staining of all groups considered; the differences in CD31 positivity between these 3 groups were not statistically significant. Staining in the fat-alone group illustrated the presence of endothelial cells homogenously distributed within the intralobular septations between adipocytes (Fig. 4E) . The 12 million group had the greatest magnitude of CD31 staining of all experimental groups, followed by the fat-alone group (*P < 0.05, Fig. 4F ).
DISCUSSION
Achieving durable soft tissue volume outcomes using a cellbased hyaluronic acid strategy has been challenging, thus far. Studies into noninjectable, spongy HA scaffolds supplemented with adiposederived stromal cells and implanted intact into a human subcutaneous in vivo model have shown proficiency for HA to serve as a cell carrier, but poor ability to promote de novo adipose tissue formation. 21 With respect to the commercially available, injectable hyaluronic acid-based fillers, complications arise in the mechanics of incorporating SVF cells into the gel. Due to the fact that these fillers arrive already crosslinked, their increased viscosity precludes sufficient homogenization after supplemented with stromal cells. To this point, Renevia may not only be amenable to cell supplementation, but may actually facilitate cell-based therapy, as evidenced by its biochemical dynamics. After the Glycosil and Gelin components are dissolved into solution, Extralink, a polyethylene glycol diacrylate cross-linker, is introduced to create the vital crosslinks that confer coherence and rigidity to the scaffold. Since this reaction requires 8 to 15 minutes to complete, Renevia begins as a low viscosity gel that mixes readily with supplemented cells and delivers easily through a syringe prior to solidifying in the target area. Moreover, Renevia's specificity for cell-based therapy is further enhanced by a synthetic architecture that emulates the natural ECM. This is exemplified by the 2 major constituents of the Renevia assembly, whereas the Glycosil component provides the hyaluronan backbone of the scaffold, Gelin contains the requisite amino acid sequences that facilitate cellular attachment and proliferation. By this mechanism, Renevia is designed to be incrementally resorbed and slowly replaced by endogenous ECM over its lifetime.
As anticipated, the fat-alone group demonstrated the greatest early volume retention. At week 8, the average graft volume retention in the fat-only group was over 49%. Prior studies using the same murine scalp model have found approximately 60% survival in fat grafts at 8 weeks, although with 200-μL grafts. 17, 22 The difference in results is in part attributable to graft size, because the adipose and scaffold grafts placed in this experiment were 250 μL in volume. It is also important to note that prior studies continued to demonstrate a negative trend in volume retention out to 12 weeks, though these differences were not statistically significant. In this present study, we followed volume retention to 16 weeks, and observed continued volume loss with fat grafts out to our later time points. The well-regarded graft survival theories of Peer, and more recently Carpaneda, predict adipocyte survival on the basis of expeditious host anastomotic revascularization, or to the proximity of adipocytes to the zone of imbibition. 23, 24 It is widely accepted that larger grafts, with their underperfused cores, have a comparatively smaller surface area to volume ratio, and are thus more susceptible to hypoxic cell damage and adipocyte death.
Initially, we saw a significant drop in volume in the hydrogel experimental groups in the days after grafting. This rapid volume loss potentially may be attributable to mobilization of fluid from the mostly water scaffold. It is possible that this was aggravated further by the intraoperative volume status of the mice during inhalational anesthesia, and reflects the fact that the mice were not receiving normal saline support. This factor can be remedied in the future through postoperative administration of a saline bolus.
The experimental arm incorporating the highest concentration of SVF cells ultimately outperformed every other group with respect to graft survival at 16 weeks. The fact that the 2 lower concentration scaffold groups performed no better than scaffold-alone-and tracked closely to it throughout the study-suggests that the concentration of 12 million cells per milliliter of scaffold exceeds a possible threshold value to produce a significant difference.
The increased vascularity in the 12 million group, as evidenced by image quantification of CD31 positivity, is consistent with our hypothesis of increased perfusion, conferring an advantage in volume retention. Predictably, the scaffold-only group performed more poorly in comparison to the fat-only group, both in volume retention as well as in CD31 positivity. This potentially may be due to native stem cells within the adipose tissue grafts, endothelial cell differentiation, and the concomitant secretion of proangiogenic growth factors.
We observed replacement of the scaffold with new ECM in the 12 million group; this was most evident when compared with the scaffold-only group. Histology of the 2 groups revealed a grossly lower proportion of continuous, intact scaffold in the 12 million group, along with increased segmentation by bridges of new ECM, fibrous tissue, and blood vessels. Additionally, the residual scaffold in the 12 million samples was studded with adipocytes, potential evidence of adipogenic differentiation of the SVF cells used for supplementation. Comparatively, the scaffold in the scaffold-only group remained broadly intact throughout the experiment, with less dissolution or replacement.
CONCLUSIONS
Stromal vascular fraction cells increase the percentage of retention of the Renevia hydrogel scaffold. While lower concentrations of SVF with Renevia performed no better than scaffold-alone, the hydrogel scaffold with the highest concentration of human SVF cells performed significantly better than all other groups including fat-alone. Thus, from the perspective of volume retention, incorporation of higher concentrations of SVF cells with Renevia may be an alternative to conventional adipose tissue grafting. In this study, we have discovered a threshold concentration of cell supplementation to observe this effect. Future investigations can focus on determining the optimum concentration of SVF cells to most efficiently accomplish the aims of cellbased therapy.
